Pipeline
We are building a robust pipeline of transformative medicines addressing cancer, inflammatory and autoimmune diseases, and fibrosis.
Using our Deep Biology platform, we are advancing multiple large molecule therapeutic candidates with the potential to be first-in-class therapeutics. Our most advanced product candidates are outlined in the chart below:
Immunology
Program
Target ID & Validation
Hit-to-Lead
Lead Optimization
TRB-051*
Lead Optimization
TRB-031*
Lead Optimization
TRB-041*
Hit-to-Lead
TRB-052*
Hit-to-Lead
TRB-061
Hit-to-Lead
TRB-000
Target ID & Validation
*In collaboration with Eli Lilly
Oncology
Program
Target ID & Validation
Hit-to-Lead
Lead Optimization
TRB-012
Lead Optimization
Immunology
Oncology
*Partnered with Eli Lilly.
Discovery Pipeline
In addition to these therapeutic programs, we are developing a broad research pipeline by applying our Deep Biology Platform, identifying novel insights into tissue immune-regulation to drive target identification.
Our Collaborations
We have established a number of collaborations and partnerships with leading industry and academic institutions. Notably, we work with Eli Lilly across 4 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, TRB-051 and TRB-052. In December 2021 we entered into a collaboration with Janssen Pharmaceutica NV for novel targets in Immunology & Inflammation.
